ISO 9001 is a general quality standard for any industry, focused on customer satisfaction and continual improvement. ISO 13485 is built for medical devices and focuses on regulatory compliance, product safety and effectiveness. It adds requirements ISO 9001 does not have: risk management across the product lifecycle, design controls and design history files, sterile and implantable device controls, process validation, traceability, complaint handling and regulatory reporting. ISO 9001 certification alone is not accepted by device regulators; ISO 13485 is.
No law mandates the certificate itself, but in practice you cannot sell most devices without an ISO 13485-compliant QMS:
Most small and mid-sized organizations need 6–12 months from gap analysis to certificate. The biggest variable is how much of your QMS already exists and how quickly you can generate implementation records. The certificate is valid for three years, with annual surveillance audits and a recertification audit before expiry.
The Medical Device Single Audit Program lets one audit by an MDSAP-recognized auditing organization satisfy the QMS requirements of five regulators: USA (FDA), Canada (Health Canada), Brazil (ANVISA), Australia (TGA) and Japan (MHLW/PMDA). MDSAP is mandatory for Canada and, in the US, FDA accepts MDSAP audit reports in place of routine FDA inspections. If you sell or plan to sell in two or more of these markets, MDSAP usually saves audit days and cost.
An internal audit is a systematic, independent examination of your organization’s Quality Management System (QMS). It helps confirm that your QMS meets ISO 13485 requirements, ensures compliance with regulatory frameworks such as FDA QSR/QMSR and EU MDR/IVDR, checks alignment with your own documented procedures, and verifies that the system is effectively implemented and maintained.
None of the three main frameworks — ISO 13485, FDA QMSR, or EU MDR — prescribe a fixed number of audits per year. Instead, they require a risk-based, planned audit program.
Bottomline: While regulations do not mandate a fixed schedule, the industry standard is to conduct at least one full-cycle internal audit each year. In addition, organizations typically perform more frequent targeted or process-specific audits for higher-risk areas to ensure ongoing compliance and effectiveness.
Yes — this is explicitly permitted under ISO 13485, and it's a common approach for smaller or resource-constrained organizations. The standard requires only that auditors be independent of the area being audited and doesn't require them to be employees.
Clause 8.2.4 is satisfied whether the audit is conducted by trained internal staff or by qualified external/contracted auditors.
A few things to keep in mind when fully outsourcing:
So the engagement can range from a single mock audit, to a fully outsourced annual program, to a hybrid where we cover specialized or higher-risk areas while your team handles the rest.
They're both audits under your QMS, but they look at different things and serve different purposes:
| Internal Audit | Supplier Audit | |
|---|---|---|
| Scope | Your own organization's QMS, processes, and departments | An external supplier's or subcontractor's quality system and processes |
| Regulatory driver | ISO 13485 Clause 8.2.4 (mandatory, planned intervals) | ISO 13485 Clause 7.4 (purchasing controls) — audits are a common but not universally mandatory verification method, depending on supplier risk |
| Purpose | Verify your own QMS conforms to the standard, regulatory requirements, and your documented procedures | Verify a supplier's ability to consistently deliver conforming product/service and meet your specifications and quality requirements |
| Who's assessed | Your process owners, departments, records | Supplier's facility, processes, records, and sometimes their own sub-tier suppliers |
| Frequency driver | Risk and importance of your internal processes | Risk classification of the supplier/component (critical suppliers audited more frequently) and their performance history |
| Outcome feeds into | Your management review, your CAPA system | Your Approved Supplier List, supplier scorecards/ratings, and your own CAPA if supplier issues affect your product |
| Typical trigger for immediate audit | Scheduled interval, or a systemic internal issue (e.g., recurring CAPA in one area) | Supplier quality complaints, incoming inspection failures, or a change in supplier's process/location |
Yes — this is now more straightforward than it used to be.
Since the FDA QMSR became effective February 2, 2026, harmonizing FDA's device quality requirements with ISO 13485:2016, a single audit built on an ISO 13485 checklist covers majority of both FDA and EU MDR expectations at once. The requirements that remain distinct to each region can be layered in:
So, the audit is one integrated exercise against a common ISO 13485 backbone, with region-specific checklists applied on top — not two entirely separate audits.
This depends on organization size, number of sites, product complexity, and scope, but as a general guide:
Total elapsed time — including planning, document review, on-site or remote execution, and the final report — is usually 2–4 weeks from kick-off to report delivery for a full audit, even though on-site time itself is much shorter.
A major non-conformance indicates a systemic failure to meet a regulatory or standard requirement, unlike a minor, isolated lapse. The typical process is:
Bottom line: Leaving a major non-conformance unresolved internally is far preferable to having the same issue surface during an FDA inspection or Notified Body surveillance audit — which underscores the value of a rigorous internal audit program.
Clinical evaluation is the continuous process of collecting and critically assessing all available clinical data on a device to show that it is safe, performs as intended and has an acceptable benefit-risk profile. Its output is the Clinical Evaluation Report (CER), which every device class needs under the EU MDR.
A clinical investigation is one possible source of that data: a planned study in human subjects, run to ISO 14155, that generates new clinical data.
| Clinical Evaluation | Clinical Investigation | |
|---|---|---|
| What it is | An ongoing assessment of all clinical data | A prospective study generating new data |
| Required for | Every device, every class (MDR Article 61) | Only when existing data are insufficient (always for most Class III and implantables) |
| Data sources | Literature, equivalent devices, PMS/PMCF data, investigations | Subjects enrolled under a protocol |
| Output | Clinical Evaluation Plan and Report (CEP/CER) | CIP and Clinical Investigation Report (CIR) |
| Governing guidance | MDR Art. 61 & Annex XIV, MEDDEV 2.7/1 Rev. 4, MDCG 2020-5/6/13 | MDR Art. 62–82 & Annex XV, ISO 14155 |
| Timing | Before certification, then updated throughout the device lifecycle | A defined start and end |
Often literature is enough, but not always. It depends on the device class, novelty and how much good-quality data already exist.
Our recommendation: start with a clinical evidence gap analysis. We assess what you already have, what your claims require, and whether a targeted PMCF study, rather than a full pre-market investigation, could close the gap. This single step often saves months and significant cost.
For Class IIa–III devices, plan for 12–18 months from Notified Body application to certificate, and longer for novel Class III devices. Notified Body fees vary widely with device class, number of devices and audit days, so request quotes from two or three Notified Bodies. Class I self-certified devices can be ready in 3–6 months once the documentation is in place.
Not for standard Class I devices. The manufacturer self-declares conformity. However, Class Is (sterile), Class Im (measuring function) and Class Ir (reusable surgical instruments) need a Notified Body for those specific aspects. All Class I devices still need full technical documentation, a CER, PMS and EUDAMED registration.
Under MDR Article 15, every manufacturer must have at least one Person Responsible for Regulatory Compliance with documented expertise. Micro and small enterprises can use an external PRRC who is permanently and continuously available. Non-EU manufacturers' Authorized Representatives must also have a PRRC.
Possibly. Regulation (EU) 2023/607 extended the transition until 31 December 2027 (Class III and Class IIb implantables) or 31 December 2028 (other classes), but only if you had an MDR-compliant QMS in place by 26 May 2024, lodged a formal MDR application by 26 May 2024, signed a written agreement with a Notified Body by 26 September 2024, and have made no significant changes to the device. If you missed these conditions, contact us urgently to review your options.
The Medical Device Marketing Authorization (MDMA) is the SFDA approval needed before a medical device or IVD can be imported, distributed or sold in Saudi Arabia. Most devices need an MDMA through the full Technical File Assessment route. Certain low-risk Class A devices may instead be listed through the Medical Device Listing route. We confirm the right route during classification.
Typical MDMA technical file contents include: Authorized Representative agreement and licence details; device description and classification rationale; ISO 13485 certificate; Declaration of Conformity; essential principles/GSPR checklist; design and manufacturing information; risk management file; verification and validation reports (biocompatibility, sterilization, electrical safety, software); clinical evidence (CER or clinical data); labeling and IFU (Arabic where required); post-market surveillance plan; and reference-market approvals such as CE certificates or FDA clearance, where available.
SFDA's official review timeframe is 35 working days, but the clock stops while you respond to questions. In practice, allow 3–6 months from submission to MDMA for a complete file, plus 1–2 months beforehand to appoint your AR and prepare the file.
Up to three years, typically aligned with the validity of your supporting certificates (e.g., ISO 13485 or CE certificate). Start the renewal at least 3–6 months before expiry to avoid gaps in market access.
Yes. Local companies that import, distribute or store medical devices need a Medical Device Establishment Licence (MDEL) from SFDA, separate from the manufacturer's MDMA and the AR licence.
Yes. Under the Medical Devices Rules, 2017, licensing became mandatory in phases: Class A and B devices from 1 October 2022, and Class C and D devices from 1 October 2023. Today, all medical devices and IVDs imported, manufactured, sold or distributed in India need the appropriate CDSCO licence.
The Rules allow the Central Licensing Authority up to nine months to decide on an import licence application. Complete, well-organized dossiers for Class A and B devices are often approved sooner; Class C and D devices take longer and may involve a site inspection or MDAC review. Fast, complete answers to deficiency letters are the most important factor you can control.
No. The application must be filed through the SUGAM/National Single Window portal by an Indian Authorized Agent, i.e., an Indian company with a valid manufacturing licence or a licence/registration to sell medical devices. That agent also becomes responsible for post-market obligations, including complaint handling, field safety notices and recalls.
Generally, yes. For devices already approved in reference countries, CDSCO usually accepts existing clinical data and may waive a local clinical investigation. For novel devices without a predicate, or where Indian population data are needed, CDSCO may require a clinical investigation in India (Form MD-22).
EUDAMED is the European Database on Medical Devices created under the EU MDR and IVDR. It gives regulators, Notified Bodies, companies and the public a single source of information on economic operators, devices, certificates, clinical investigations, vigilance and market surveillance. It is organized into six modules: Actor registration; UDI/Device registration; Notified Bodies & Certificates; Clinical Investigations & Performance Studies; Vigilance & Post-Market Surveillance; and Market Surveillance.
Following Commission Decision (EU) 2025/2371 and Regulation (EU) 2024/1860, four modules became mandatory on 28 May 2026: Actor registration, UDI/Device registration, Notified Bodies & Certificates, and Market Surveillance. Key transition dates:
The Vigilance and Clinical Investigation modules will become mandatory later, once declared functional.
A Single Registration Number (SRN) is the unique ID issued to manufacturers, Authorized Representatives and importers when they register in the EUDAMED Actor module. The competent authority of the Member State where you (or your EU AR) are established validates your registration. You need an SRN before you can apply to a Notified Body or register devices, so it is usually the first step.
For each device: the Basic UDI-DI and UDI-DI, device name and model, risk class, EMDN nomenclature code, intended purpose, sterility and implantable status, whether it contains substances such as medicinal products or CMR/endocrine disrupting substances, certificate details, and the SRN of the manufacturer and AR. For Class III and implantable devices, the Summary of Safety and Clinical Performance (SSCP) is also published.
PMS is the proactive, systematic process of collecting and reviewing experience from devices already on the market, including complaints, incidents, literature, registries, user feedback and PMCF data, to confirm they remain safe and perform as intended, and to trigger corrective action when they do not. Under the EU MDR, PMS is a legal obligation for every device class and is one of the areas Notified Bodies examine most closely.
| Document | Required for | Frequency |
|---|---|---|
| PMS Plan (Annex III) | All classes | Maintained as part of the technical documentation |
| PMS Report (PMSR, Art. 85) | Class I | Updated when necessary |
| Periodic Safety Update Report (PSUR, Art. 86) | Class IIa | At least every 2 years |
| PSUR | Class IIb and III | At least annually; Class III and implantable PSURs are reviewed by the Notified Body |
| PMCF Plan and Evaluation Report | All classes (or justified absence) | Updated with the CER |
Serious incidents must be reported to the competent authority immediately after a causal relationship is established or reasonably possible, and no later than 15 days after becoming aware; 10 days for death or unanticipated serious deterioration in health; and 2 days for a serious public health threat. Field Safety Corrective Actions must be reported before they are carried out (unless urgent), and statistically significant increases in non-serious incidents must be trend-reported (Article 88).
Yes. Many manufacturers outsource literature monitoring, complaint trending, PSUR/PMSR writing and PMCF evaluation. You remain legally responsible, but an experienced partner keeps the process running on schedule and to Notified Body expectations. We offer PMS as a retainer service with a fixed annual calendar of deliverables.
A CER documents the clinical evaluation of a device: the critical appraisal of clinical data from literature, equivalent devices, clinical investigations and post-market experience, showing that the device meets the relevant GSPRs for safety and performance and has an acceptable benefit-risk profile. It is required for every device class under the EU MDR (Article 61 and Annex XIV) and requested by CDSCO for Class C and D devices and by SFDA as part of clinical evidence.
A Clinical Evaluation Plan; device description and intended purpose; state-of-the-art analysis (current treatment options and benchmarks); equivalence demonstration, if used; the literature search protocol and results; appraisal and analysis of all clinical data; benefit-risk analysis; PMS and PMCF data; residual risks and gaps; and conclusions signed by qualified evaluators. For Class III and implantables, the CER also underpins the Summary of Safety and Clinical Performance (SSCP).
The CER is a living document. Under the MDR it must be updated with PMS data. In practice, Notified Bodies expect annual updates for Class III and implantable devices (in line with the PSUR), and updates every 2–5 years for lower-risk devices, justified in the CEP. Update it sooner if new safety information, a design change or a new indication arises.
MEDDEV 2.7/1 Rev. 4 expects evaluators to have a relevant degree plus five years of professional experience (or ten years without a degree) in research methodology, device technology and the relevant clinical field, with a signed declaration of interests. Our CERs are written by experienced medical writers and reviewed by clinical and biostatistical experts.
The most common findings are: an insufficient state-of-the-art section; equivalence claims without enough technical, biological and clinical comparison; literature searches that are not reproducible; data that do not support every claim in the IFU; missing quantitative safety and performance acceptance criteria; and a PMCF plan that does not address identified gaps. We run a Notified Body-style review against these points before submission.
Tell us about your device and target market. Our regulatory specialist, not a salesperson, will reply within one business day.
We use essential cookies to run this site. With your permission we also use analytics and marketing cookies (HubSpot, Google) to see which pages and ads bring enquiries. Read more about cookies